131![Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells](https://www.pdfsearch.io/img/11798e241f3c7f6b14fd92e3adea8a88.jpg) | Add to Reading ListSource URL: www.nature.comLanguage: English - Date: 2013-11-21 09:53:44
|
---|
132![Hindawi Publishing Corporation Case Reports in Hematology Volume 2015, Article ID[removed], 4 pages http://dx.doi.org[removed][removed]Case Report Hindawi Publishing Corporation Case Reports in Hematology Volume 2015, Article ID[removed], 4 pages http://dx.doi.org[removed][removed]Case Report](https://www.pdfsearch.io/img/04eb5df2ec48976d539435752e7ec05c.jpg) | Add to Reading ListSource URL: downloads.hindawi.comLanguage: English - Date: 2015-02-10 03:08:07
|
---|
133![SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of](https://www.pdfsearch.io/img/299a024245dc5a9553c62e888c25a96d.jpg) | Add to Reading ListSource URL: www.scottishmedicines.org.ukLanguage: English |
---|
134![SGI-110, a novel 5-aza-2’-deoxycytidine containing dinucleotide, induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells Abstract #681 Elizabeth A. Griffiths1, Pragya Srivastava1, Golda Collamat SGI-110, a novel 5-aza-2’-deoxycytidine containing dinucleotide, induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells Abstract #681 Elizabeth A. Griffiths1, Pragya Srivastava1, Golda Collamat](https://www.pdfsearch.io/img/120f671029835738d7e3d26340812ca1.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
135![Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapse Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapse](https://www.pdfsearch.io/img/5981af407da08b0c5c1d1f62606ab4a5.jpg) | Add to Reading ListSource URL: astx.comLanguage: English - Date: 2013-05-20 15:28:50
|
---|
136![Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory](https://www.pdfsearch.io/img/1d01283ad427d7b5cbf06b1a7d4c5535.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
137![First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Jean Pierre Issa, MD Fels Institute, Temple Univ First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Jean Pierre Issa, MD Fels Institute, Temple Univ](https://www.pdfsearch.io/img/5cdc50dd84a52fd17a51d421dde94bdb.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
138![Abstract No[removed]Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML) Simone Jueliger1, Abstract No[removed]Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML) Simone Jueliger1,](https://www.pdfsearch.io/img/8fa9875d1aaeb451eaf08393dba59e01.jpg) | Add to Reading ListSource URL: astx.comLanguage: English |
---|
139![LC Paper No. CB[removed]) 7 March 2005 Dear Legislative Councillors, Subject: Standard Drug Formulary and Public Healthcare System On behalf of Chronic Myeloid Leukaemia (CML) and Gastrointestinal Stromal Tumour ( LC Paper No. CB[removed]) 7 March 2005 Dear Legislative Councillors, Subject: Standard Drug Formulary and Public Healthcare System On behalf of Chronic Myeloid Leukaemia (CML) and Gastrointestinal Stromal Tumour (](https://www.pdfsearch.io/img/cb30f70b907fabb815fff9cc8aadb1de.jpg) | Add to Reading ListSource URL: www.legco.gov.hkLanguage: English - Date: 2005-10-19 22:47:56
|
---|
140![Microsoft Word - FINAL CML Report dated 28 September 04.doc Microsoft Word - FINAL CML Report dated 28 September 04.doc](https://www.pdfsearch.io/img/91be1c69bd657ffa20b16b3f590703e9.jpg) | Add to Reading ListSource URL: www.otago.ac.nzLanguage: English |
---|